

Assets	View Mor
Xevinapant	
IAPs inhibitor	
Development Phase III	
Tepotinib	
MET kinase inhibitor	
Development Phase III	
M1231	
MUC1xEGFR	
Development Phase I	

Updated: May 2022

EMD Serono is the Healthcare business of Merck KGaA, Darmstadt, Germany in the U.S. and Canada.

Pipeline compounds are being investigated for the treatment of various diseases. Efficacy and safety of these compounds are still under investigation in various indications. Regulatory approval is dependent on the completion of the study programs and review by local regulatory authorities, and varies from country to country. Clinical trial information is available at www.clinicaltrials.gov.

©2022 Merck KGaA, Darmstadt, Germany or its affiliates. All rights reserved. EMD Serono is the Healthcare business of Merck KGaA, Darmstadt, Germany in the U.S. and Canada. All product names are registered trademarks of Merck KGaA, Darmstadt, Germany or its affiliates.




<sup>\*</sup> Phase II study in combination with avelumab





#### IMMUNO-ONCOLOGY D



1L, first-line treatment. 2L, second-line treatment.

<sup>1</sup>Avelumab is being co-developed and co-marketed by Merck Healthcare KGaA, Darmstadt, Germany and Pfizer Inc.

EMD Serono is the Healthcare business of Merck KGaA, Darmstadt, Germany in the U.S. and Canada.

Pipeline compounds are being investigated for the treatment of various diseases. Efficacy and safety of these compounds are still under investigation in various indications. Regulatory approval is dependent on the completion of the study programs and review by local regulatory authorities, and varies from country to country. Clinical trial information is available at www.clinicaltrials.gov.


©2022 Merck KGaA, Darmstadt, Germany or its affiliates. All rights reserved. EMD Serono is the Healthcare business of Merck KGaA, Darmstadt, Germany in the U.S. and Canada. All product names are registered trademarks of Merck KGaA, Darmstadt, Germany or its affiliates.







#### DNA DAMAGE RESPONSE (DDR)



2L, second-line treatment.

EMD Serono is the Healthcare business of Merck KGaA, Darmstadt, Germany in the U.S. and Canada.

Pipeline compounds are being investigated for the treatment of various diseases. Efficacy and safety of these compounds are still under investigation in various indications. Regulatory approval is dependent on the completion of the study programs and review by local regulatory authorities, and varies from country to country. Clinical trial information is available at www.clinicaltrials.gov.

©2022 Merck KGaA, Darmstadt, Germany or its affiliates. All rights reserved. EMD Serono is the Healthcare business of Merck KGaA, Darmstadt, Germany in the U.S. and Canada. All product names are registered trademarks of Merck KGaA, Darmstadt, Germany or its affiliates.




<sup>\*</sup> EMD Serono-National Cancer Institute collaborative studies





#### ONCOGENIC PATHWAYS





EMD Serono is the Healthcare business of Merck KGaA, Darmstadt, Germany in the U.S. and Canada.

Pipeline compounds are being investigated for the treatment of various diseases. Efficacy and safety of these compounds are still under investigation in various indications. Regulatory approval is dependent on the completion of the study programs and review by local regulatory authorities, and varies from country to country. Clinical trial information is available at www.clinicaltrials.gov.

